

## COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

## RECENT NEWS

### [Propanc Biopharma Enters Into a \\$3 Million Financing with Institutional Investor](#)

Mar 31 2020, 9:00 AM EDT

### [Propanc Biopharma's Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, Spain](#)

Mar 16 2020, 8:30 AM EDT

### [Propanc Biopharma Receives Advance Overseas Finding from Innovation and Science Australia](#)

Jan 21 2020, 8:30 AM EST

## STOCK OVERVIEW

Symbol	PPCB
Exchange	OTCQB
Market Cap	72.66k
Last Price	\$0.02075
52-Week Range	\$0.01956 - \$7.00

04/08/2020 03:58 PM EDT

## INVESTOR RELATIONS

Propanc Biopharma, Inc.  
T: +61-03-9882-6723  
[irteam@propanc.com](mailto:irteam@propanc.com)

## MANAGEMENT TEAM

**James Nathanielsz**  
CEO, Executive Chairman

**Dr. Julian Kenyon, M.D.**  
Chief Scientific Officer

**Carlo Campiciano**  
Chief Financial Officer and Secretary

**Professor Klaus Kutz, M.D.**  
Chief Medical Officer

## PROPANC BIOPHARMA, INC.

302/6 Butler Street  
Camberwell, VIC 3124  
AU

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.